OrganiGram Holdings Inc (OTCMKTS:OGRMF) is on the outside looking in at CGC, ACB, and APHA as far as the elite group of global cannabis powers. But OGRMF might be high on the list of potential candidates to enter that class next. One factor that defines the top group is diversification, both in terms of geography and revenue streams, with strategic investments being a major part of that equation.
One move recently made by the company that you may have missed highlights how it may be making a fresh push in Q4 and Q1 2019 for more global diversification through strategic investments: the company announced a couple weeks ago that it has acquired 8,333 common shares of alpha-cannabis Pharma GmbH (a German cannabis name), representing a 25% stake, for aggregate proceeds of €1,625,000. This is exactly the type of deal that can push OGRMF into that top tier.
OrganiGram Holdings Inc (OTCMKTS:OGRMF) is a TSX Venture Exchange listed company whose wholly owned subsidiary, OrganiGram Inc., is a licensed producer of medical marijuana in Canada.
OrganiGram is focused on producing the highest quality, condition-specific medical marijuana for patients in Canada. OGRMF’s facility is located in Moncton, New Brunswick and the Company is regulated by the Access to Cannabis for Medical Purposes Regulations.
The company’s own portrayal of its market positioning runs as follows: “From the day we started back in 2013, it’s been about making lives better – for our clients, our people, and our community. We’re based in Moncton, New Brunswick, the heart of the Maritimes, but at OrganiGram Holdings we’re committed to improving the quality of life for Canadians across the country. For us, this means working with health-care providers and industry organizations, supporting research and education, and providing a safe, effective product.”
“To be effective in that last goal, we made a decision to produce organic cannabis. Growing certified organic medical cannabis isn’t easy, in fact, most licensed producers won’t take this on. It means more care, more testing, more rules… but in the end, it means a product that we feel delivers on our goals in the best way. And improving the quality of life for Canadians is not just about getting safe, quality product to them effectively. It’s about creating jobs, being good neighbors and contributing to our community.”
Movin’ On Up
OrganiGram Holdings Inc (OTCMKTS:OGRMF) managed to rope in revenues totaling $3.7M in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of 94.3%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($155.8M against $9.1M).
According to the release, Alpha-Cannabis’ Managing Directors Alexander Klomsdorff and newly appointed Dr. Volker Christoffel are pleased that the agreement with Organigram has now been formally finalized. ACG has been preparing the development and production of further cannabis based products for the swiftly growing German and European Markets following their recent product launch of “Cannabidiol alpha DAC”. “We look forward to a strong and fruitful partnership with our Canadian partners as we see significant potential in jointly materializing the medicinal benefits of Cannabinoids” ACG’s Managing Directors stated.
While this is a clear factor, it has been incorporated into a trading tape characterized by a pretty dominant offer, which hasn’t been the type of action OGRMF shareholders really want to see. In total, over the past five days, shares of the stock have dropped by roughly -4% on above average trading volume. All in all, not a particularly friendly tape, but one that may ultimately present some new opportunities.
“As we continue to build the framework of our international medical business, finding the right partners in the right markets has been a priority for our company,” stated Greg Engel, CEO at Organigram. “This relationship is a perfect example of two companies coming together towards a common goal, and we’re very excited to build our business in Germany through our partners at alpha-cannabis Pharma GmbH”
Generex Biotechnology Corporation (OTCMKTS:GNBT) Submits Pre-IND For Ii-Key-SARS-CoV-2 Vaccine To The FDA
Post Views: 121 Generex Biotechnology Corporation (OTCMKTS:GNBT) submitted a Pre-IND update to the FDA outlining its proposed Phase I/II clinical...
cbdMD Inc. (NYSEAMERICAN:YCBD) Protecting Its CBD Technologies Through Patents and expands Partnership With Bellator MMA
Post Views: 280 cbdMD Inc. (NYSEAMERICAN:YCBD) announced an extension of the exclusive Official CBD marketing partnership with ViacomCBS’s wholly-owned subsidiary...
CLS Holdings USA Inc (OTCMKTS:CLSH) Increases Revenues In June 2020 By 5.35%
Post Views: 181 CLS Holdings USA Inc (OTCMKTS:CLSH) posted a growth of 5.35% YoY to $1.102 million in June 2020....
Canopy Rivers Inc.’s (OTCMKTS:CNPOF) Portfolio Companies Expanding Their Reach In Canada And The US
Post Views: 234 Canopy Rivers Inc.’s (OTCMKTS:CNPOF) three portfolio companies recently announced plans to expand their product offering for recreational...
AgraFlora Organics International Inc. (OTCMKTS:AGFAF) Processes Around 1,000KG Of CBD Crude Oil From 10,000Kg Of Hemp
Post Views: 300 AgraFlora Organics International Inc. (OTCMKTS:AGFAF) Toronto-based Sustainable Growth Strategic Capital Corp subsidiary in partnership with MicroC45 produced...
Marimed Inc (OTCMKTS:MRMD) Retires $7.3 Million Short-term Debt: Robust Sales Of Adult-Use Programs Improves Cash Flow
Post Views: 167 Marimed Inc (OTCMKTS:MRMD) restructured its debt to provide financial flexibility at reduced interest rates. Marimed replaced the...